A key patient advocate sees the final 2023 exchange rule as a mixed bag for reducing drug prices. Carl Schmid, executive director at the HIV+Hepatitis Policy Institute, touts the requirement that insurers offer standardized health plan options alongside any non-standardized Qualified Health Plans (QHPs) as a positive step for patients that rely on prescription drugs. However, Schmid is upset that the administration continues to avoid requiring insurers to count copay assistance toward out-of-pocket costs. Federal exchange insurers must include standardized...